# Cerebrum and Cardiac Protection With Allopurinol in Neonates With Critical Congenital Heart Disease Requiring Cardiac Surgery With Cardiopulmonary Bypass

> **NCT04217421** · PHASE3 · RECRUITING · sponsor: **dr. M.J.N.L. Benders** · enrollment: 236 (estimated)

## Conditions studied

- Congenital Heart Disease in Children
- Neuroprotection

## Interventions

- **DRUG:** Allopurinol
- **DRUG:** Mannitol

## Key facts

- **NCT ID:** NCT04217421
- **Lead sponsor:** dr. M.J.N.L. Benders
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-02-14
- **Primary completion:** 2026-10-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 236 (ESTIMATED)
- **Last updated:** 2024-05-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04217421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04217421, "Cerebrum and Cardiac Protection With Allopurinol in Neonates With Critical Congenital Heart Disease Requiring Cardiac Surgery With Cardiopulmonary Bypass". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT04217421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*